Comprehensive Report on the Investigational Compound LY3872386

I. Executive Summary

LY3872386 was an investigational small molecule compound developed by Eli Lilly and Company, primarily targeting atopic dermatitis. Classified therapeutically as an anti-inflammatory agent for skin disorders, its specific mechanism of action remained undefined throughout its development.1 The compound advanced to Phase 1 clinical evaluation in a multicenter, multifaceted study (NCT06119529) designed to assess its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with atopic dermatitis.2 However, clinical development was abruptly terminated in July 2024, reportedly due to "emerging nonclinical data".1 This early-stage termination, occurring relatively shortly after trial initiation, suggests the discovery of a significant safety or developability concern in concurrent or newly reviewed nonclinical studies, leading to a swift cessation of human investigation.

II. Introduction to LY3872386

A. Compound Identification and Originator

The investigational drug LY3872386, also referred to as LY 3872386, was under development by Eli Lilly and Company.1 As a novel therapeutic candidate, it represented an effort by a major pharmaceutical entity to address unmet needs in dermatological conditions.

B. Pharmacological Classification

LY3872386 was identified as a small molecule drug.4 Its intended therapeutic applications placed it within the categories of "Anti-inflammatories" and "Skin disorder therapies".1 It was designated as a New Molecular Entity (NME), indicating a chemical structure not previously approved for therapeutic use.1 The compound did not hold Orphan Drug Status.1

C. Mechanism of Action